Navigation Links
Karmanos Cancer Institute Seeks Breast Cancer Patients to Participate in a New Drug Trial
Date:11/10/2008

DETROIT, Nov. 10 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Institute is looking for women with HER2 positive metastatic breast cancer to participate in a clinical trial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO)

The Phase II trial at Karmanos is part of an international study to further test a new drug Trastuzumab-DM1, in development by Genentech. The trial will be under the direction of Patricia LoRusso, D.O., Karmanos director of the Phase I Clinical Trials Program and professor of internal medicine at Wayne State University.

"We are actively recruiting women to join this study and encourage them to call us for additional information," said Dr. LoRusso. She stated that eligible patients must have HER2 positive metastatic breast cancer, tumors measurable by radiographic evaluation, progressed on Herceptin, Tykerb and Xeloda, and show no current evidence of brain cancer.

Patients should call the Karmanos Clinical Trials office at 313-576-8749.

Dr. LoRusso has developed the Phase I program at Karmanos, one of only 14 National Cancer Institute (NCI)-funded Phase I programs in the country, and the only such program in Michigan. She has been integrally involved in the early clinical development of several drugs that are now commercially available.

The Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 facul
'/>"/>

SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Danialle Karmanos Work It Out (DKWIO) Site Earns Recognition for Web Excellence
2. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
3. J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
4. Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services
5. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
6. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
7. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
8. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
9. Danialle Karmanos Work It Out Launches Dynamic Blog
10. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
11. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Abortion, Bishops, and Healthcare: Announcing 'Deaf at the Cathedral' Tour in Nine States. 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:Ifbyphone's Virtual Call Center Software Saves DiabetesAmerica Over $240,000 Per Year 2Health News:Ifbyphone's Virtual Call Center Software Saves DiabetesAmerica Over $240,000 Per Year 3Health News:LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4
Other Medicine News:Health News:AMN Healthcare Reports Second Quarter 2008 Results 2Health News:AMN Healthcare Reports Second Quarter 2008 Results 3Health News:AMN Healthcare Reports Second Quarter 2008 Results 4Health News:AMN Healthcare Reports Second Quarter 2008 Results 5Health News:AMN Healthcare Reports Second Quarter 2008 Results 6Health News:AMN Healthcare Reports Second Quarter 2008 Results 7Health News:AMN Healthcare Reports Second Quarter 2008 Results 8Health News:AMN Healthcare Reports Second Quarter 2008 Results 9Health News:AMN Healthcare Reports Second Quarter 2008 Results 10Health News:AMN Healthcare Reports Second Quarter 2008 Results 11Health News:AMN Healthcare Reports Second Quarter 2008 Results 12Health News:AMN Healthcare Reports Second Quarter 2008 Results 13Health News:Washington Dental Service Encourages Dental Checkups as Part of Back-to-School Routine 2Health News:Washington Dental Service Encourages Dental Checkups as Part of Back-to-School Routine 3Health News:Ortho-McNeil initiates first-of-its-kind skin infection registry 2Health News:Americans Drinking Less Alcohol 2Health News:Comar, Inc. Launches AccuCup(TM) - A Printed Dosage Cup for Use in General and Pediatric Markets 2Health News:Researchers Find Genes That Influence West Nile Virus 2Health News:Researchers Find Genes That Influence West Nile Virus 3
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 2HealthSport, Inc. Closes Stock Purchase Agreement With SMI Manufacturing - Receives $2.5 Million 3Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Gu 58183 1Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Gu 58183 2Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Gu 58183 3Right to Health Care Debated at New ProCon org Website 58181 1Right to Health Care Debated at New ProCon org Website 58181 2R Kerry Clark and Robert J Palmisano Join Bausch 26 Lomb Board of Directors 58179 1R Kerry Clark and Robert J Palmisano Join Bausch 26 Lomb Board of Directors 58179 2